ESMO Asia 2022 | Phase II trial of cabozantinib for patients with HCC previously treated with IO

Stephen L. Chan, MBBS (HK), MRCP (UK), FHKCP, FHKAM (Medicine), FRCP (Edin), FRCP (Lond), Chinese University of Hong Kong, Hong Kong, discusses a Phase II trial investigating the efficacy and safety of cabozantinib for patients with hepatocellular carcinoma (HCC) who have been previously treated with immunotherapy (IO). The trial took place in Hong Kong and Korea and involved 47 patients. Results showed a progression-free survival (PFS) of 4.1 months, an overall survival (OS) of 9.9 months, and a 1-year survival rate of 45.3%. Patients who had been previously treated with atezolizumab or bevacizumab were found to achieve better outcomes compared to the cohort as a whole. This interview took place at the European Society for Medical Oncology (ESMO) Asia congress 2022 in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.